Dacomitinib Found Not to Improve Overall Survival in Patients with Advanced NSCLC
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, researchers have found that dacomitinib, an irreversible pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), was not effective at improving overall survival in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy and an epidermal growth factor (EGFR) TKI.
In the phase 3 double-blind, placebo-controlled study, researchers randomly assigned 720 patients to receive either dacomitinib or placebo. Patients treated with dacomitinib were followed for a median of 23.4 months and patients given placebo were followed for a median of 24.4 months.
They found that patients in the dacomitinib group had a median overall survival 6.83 months, while those in the placebo group had an overall survival of 6.21 months (HR 1.00 [95% CI 0.83-1.21]; P=0.506). Patients in the dacomitinib group had progression-free survival nearly twice as long as the placebo group (median 2.66 months versus 1.38 months, respectively; HR 0.66 [95% CI 0.55-0.79]; P<0.0001). Patients taking dacomitinib had a longer time to worsening of lung cancer symptoms than the placebo group.
The findings suggest that dacomitinib should not be recommended for the treatment of patients with advanced NSCLC previously treated with chemotherapy and an EGFR TKI.
Dacomitinib was not effective at improving overall survival in advanced NSCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer